Đang chuẩn bị liên kết để tải về tài liệu:
Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
In metastatic colorectal cancer (mCRC), the localization of the primary tumour has been shown to be of prognostic as well as predictive relevance. | Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT Arbeitsgemeinschaft Medikamentöse Tumortherapie